Pα+ Psychedelic Bulletin #185: Joe Rogan on Ibogaine; Wisconsin Medicaid to Cover IV Ketamine for Depression; Inside the Plan to Make Lykos MAPS Again Post published:January 11, 2025 Post category:Psychedelic Bulletin/Pα+
Billionaire Investor Antonio Gracias Plots $100M Lykos Takeover with Doblin’s Backing Post published:January 10, 2025 Post category:Analysis/News/Pα+
From Fringe to Focus: APA’s American Journal of Psychiatry Publishes Special Issue on Psychedelics Post published:January 7, 2025 Post category:Analysis/News/Pα+
Natural Medicine Advisory Bulletin 15: A Duplicitous December Post published:January 6, 2025 Post category:Colorado Natural Medicine Advisory Bulletin
Pα+ Psychedelic Bulletin #184: Federal Psychedelics Lobbying Jumps 90% in Q3’24, with MDMA-AT the Key Topic Post published:December 31, 2024 Post category:Psychedelic Bulletin/Pα+
Psychedelic Alpha’s Top 11 Stories from 2024 Post published:December 26, 2024 Post category:2024 Year in Review/Analysis/News
SCOOP: PSFC’s $130M Roadmap to Shape the Future of Psychedelic Philanthropy Post published:December 20, 2024 Post category:Analysis/News/Pα+
Pα+ Psychedelic Bulletin #183: UW Madison’s Psychedelic Symposium; MindMed Doses First Phase 3 Patient; Beckley’s IV Psilocin Readout; Psilocybin for COVID Clinicians Post published:December 18, 2024 Post category:Psychedelic Bulletin/Pα+
Bullish on Chaos: Matt Zorn on How Psychedelics Could Benefit from Trump’s Second Term Post published:December 13, 2024 Post category:Interviews
Pα+ Psychedelic Bulletin #182: Psychedelics Insiders’ Trump 2.0 Wishlist; Doblin Reflects on Lykos’ Strategy; Polish Psilocybin Study Scores $4M in Funding Post published:December 10, 2024 Post category:Psychedelic Bulletin/Pα+